FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... September 10, 2025 Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why January 27, 2022 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 First-of-its-kind app for patients on clinical trials being piloted by Cancer... November 28, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in...
